MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
MannKind Corporation DPO Ratio 2011-2026 | MNKD
Annual DPO Ratio MannKind Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 108 | 171 | 180 | 205 | 136 | 125 | 62.5 | 95.9 | 148 | 23.8 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 205 | 23.8 | 126 |
Quarterly DPO Ratio MannKind Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 178 | 152 | 143 | - | 228 | 136 | 200 | - | 387 | 271 | 206 | - | 161 | 163 | 313 | - | 204 | 147 | 130 | - | 142 | 139 | 114 | - | 61.6 | 101 | 115 | - | 92.6 | 96.3 | 141 | - | 139 | 125 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 387 | 61.6 | 165 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alector
ALEC
|
13.8 | $ 2.19 | -9.77 % | $ 226 M |  USA |
 |
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | USA |
 |
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | USA |
 |
Codexis
CDXS
|
98.4 | $ 1.02 | 1.49 % | $ 74.9 M | USA |
 |
Cerus Corporation
CERS
|
242 | $ 2.6 | 1.37 % | $ 480 M | USA |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Cellectis S.A.
CLLS
|
975 | $ 3.87 | -0.39 % | $ 116 M |  France |
 |
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
4.39 K | - | 4.01 % | $ 150 M |  Canada |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
AIkido Pharma
AIKI
|
32.8 K | - | 1.93 % | $ 17.4 M | USA |
 |
Collegium Pharmaceutical
COLL
|
34.6 | $ 41.75 | 0.19 % | $ 1.32 B | USA |
 |
Albireo Pharma
ALBO
|
1.59 K | - | -0.23 % | $ 916 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
785 | $ 36.14 | 1.23 % | $ 3.75 B | USA |
 |
Amarin Corporation plc
AMRN
|
190 | $ 13.98 | 1.27 % | $ 5.7 B |  Irlanda |
 |
Catalyst Pharmaceuticals
CPRX
|
58.1 | $ 23.77 | 2.99 % | $ 2.91 B | USA |
 |
Cardiff Oncology
CRDF
|
406 | $ 1.94 | 0.01 % | $ 130 M | USA |
 |
Curis
CRIS
|
3.24 K | $ 1.1 | -3.51 % | $ 6.94 M | USA |
 |
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M | Canada |
 |
CorMedix
CRMD
|
216 K | $ 7.16 | 0.42 % | $ 364 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.85 K | - | -11.43 % | $ 502 K | USA |
 |
Champions Oncology
CSBR
|
64.6 | $ 6.14 | 3.89 % | $ 83.9 M | USA |